HomeNewsBusinessCompaniesOnly IndiGo may have this 'flexibility' among its Indian peers, but is the time right?

Only IndiGo may have this 'flexibility' among its Indian peers, but is the time right?

The airline wants to sell and leaseback its owned aircraft. Much of it though depends on how much value it can derive for these assets in a distressed market

June 18, 2020 / 14:46 IST
Story continues below Advertisement

IndiGo's plan to put some of its owned aircraft in the market to raise funds underlines the unique position India's largest airline has in the industry.

The airline has 29 owned aircraft, which include ATRs and A320s. Rest of its peers in the domestic industry have a fleet that is mostly based on sale and lease back model. Few own the aircraft they operate.

Story continues below Advertisement

"The bottom line is, no other private airline seems to have this flexibility,"  says Nitin Sarin, Managing Partner of Sarin & Co, which specialises in aviation law. National carrier Air India, adds Sarin, does own some of its aircraft.

At the same time, IndiGo may find itself in a market that is distressed, and has many more airlines trying to do the same - sell and lease back, or sub-lease, their planes.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show